

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Kaisa Health Group Holdings Limited**  
**佳兆業健康集團控股有限公司**  
*(Incorporated in Bermuda with limited liability)*  
**(Stock Code: 876)**

**GRANT OF SHARE OPTIONS**

This announcement is made pursuant to Rule 17.06A of the Listing Rules.

The Board announces that on 26 August 2021, the Company has granted to three eligible participants, subject to their acceptance, share options to subscribe for an aggregate of 80,000,000 Shares (upon exercise in full and subject to adjustment in accordance with the Share Option Scheme) under the Share Option Scheme. Details of such grant are set out below.

Date of Grant	:	26 August 2021
Exercise price of share options granted	:	HK\$0.45 per Share, representing approximately 149% of the average closing price of HK\$0.302 per Share as stated in the Stock Exchange's daily quotations sheets for five business days immediately preceding the Date of Grant
Total number of Shares to be issued upon exercise in full of the share options granted	:	80,000,000 Shares
Closing price of the Shares on the Date of Grant	:	HK\$0.275 per Share
Average closing price of the Shares for the five business days immediately preceding the Date of Grant	:	HK\$0.302 per Share

Validity period of the share options	:	10 years from the Date of Grant
Vesting schedule of the share options	:	as to (i) 30% at any time after the expiration of 12 months from the Date of Grant; (ii) 30% at any time after the expiration of 24 months from the Date of Grant; and (iii) 40% at any time after the expiration of 36 months from the Date of Grant
Consideration for the grant of the share options	:	HK\$1 to be paid by each Grantee upon the acceptance of the share options granted

As at the Date of Grant, the Company had 5,042,139,374 Shares in issue.

The exercise of the share options by the Grantees is conditional upon the fulfilment of certain performance targets relating to the Company determined by the Board which are specified in the grant letters of the Grantees.

No share option has been granted by the Company under the Share Option Scheme within the 12-month period prior to the Date of Grant. None of the Grantees is a Director, chief executive or substantial shareholder of the Company, or any of their respective associates.

## **DEFINITIONS**

In this announcement, unless the context otherwise requires, the following expressions shall have the meaning set out below:

“associate(s)”	has the same meaning as ascribed to it under the Listing Rules
“Board”	the board of Directors
“Company”	Kaisa Health Group Holdings Limited, a company incorporated in Bermuda with limited liability and the issued Shares of which are listed on the Main Board of the Stock Exchange (stock code: 876)

“Date of Grant”	26 August 2021
“Director(s)”	the director(s) of the Company
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Share(s)”	ordinary share(s) of HK\$0.00125 each in the share capital of the Company
“Share Option Scheme”	the share option scheme of the Company approved and adopted by the Company at the special general meeting of the Company held on 8 June 2015
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“%”	per cent.

On behalf of the Board  
**Kaisa Health Group Holdings Limited**  
**Zhang Huagang**  
*Chairman*

Hong Kong, 26 August 2021

*As at the date of this announcement, the Board comprises five executive Directors, namely Mr. Zhang Huagang (Chairman), Mr. Luo Jun (Co-Vice Chairman), Mr. Wu Tianyu (Co-Vice Chairman), Mr. Kwok Ying Shing, and Ms. Kwok Ho Lai and three independent non-executive Directors, namely Dr. Liu Yanwen, Dr. Lyu Aiping, and Ms. Li Yonglan.*